Latest Financial Results News

Magellan Financial Group reported a 5% rise in operating profit for FY25 despite a 31% drop in statutory net profit, driven by strong growth in assets under management and booming income from strategic partnerships.

Perpetual Limited is set to record a significant $153.7 million non-cash impairment for FY25, largely driven by challenges in its J O Hambro boutique. This move underscores ongoing asset outflows but leaves liquidity intact.

Magellan Financial Group has announced a fully franked total dividend of AUD 0.469 per share, combining a final dividend, a performance fee dividend, and a special dividend for the six months ending June 2025.

Magellan Financial Group reported a 31% drop in net profit after tax for FY25, yet operating profit rose 5%, supported by strategic partnerships and an 8.2% increase in assets under management. The Board declared a special fully franked dividend, signaling confidence in future earnings.

Whitefield Income Limited has reported a $7.8 million net profit in its first seven months as an ASX-listed company, alongside steady monthly dividends annualised at 8%. The company’s portfolio outperformed its benchmark, signaling a promising start post-IPO.

Monash IVF Group has completed an independent review into two separate clinic incidents involving non-standard IVF treatments, revealing human errors and IT system issues. The company commits to enhanced safeguards without expecting significant financial impact.

Schaffer Corporation Limited reported a 1.5% increase in revenue to $229.7 million for FY2025, despite a 10.3% decline in net profit to $24.3 million. The company declared a fully franked final dividend of 45 cents per share, maintaining total dividends at 90 cents for the year.

Lycopodium Limited delivered robust FY25 financial results, hitting the top end of guidance with $339.6 million revenue and $42.2 million net profit. The company’s strategic SAXUM acquisition broadens its footprint in the Americas, positioning it well for growth in critical minerals and clean energy sectors.

Pharmx Technologies reported a 13% increase in FY25 revenues to $7.53 million, driven by strong growth across its Gateway and Marketplace platforms. The company maintained positive EBITDA and a solid cash position despite legal expenses, setting the stage for an ambitious FY26 growth strategy.

Pharmx Technologies has reported a 13% revenue increase to $7.5 million for FY25, driven by expanded partnerships and platform innovations, despite a dip in EBITDA due to heavy investment.

Lycopodium Limited delivered FY25 results at the top end of guidance, reporting strong revenue and profit growth alongside strategic moves to deepen its global footprint, notably through the acquisition of Argentinian engineering firm SAXUM.

Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.